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Highlights 
 A combined clinical cell-cycle risk (CCR) score has demonstrated in numerous retrospective 
studies to improve risk stratification compared to clinical variables alone. 
 CCR score thresholds were developed to select men for active surveillance (AS).   
 Owing to improved risk stratification, these thresholds should improve selection of AS 
candidates over clinical features alone.  
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ABSTRACT  
Background: A combined clinical cell-cycle risk (CCR) score that incorporates prognostic 
molecular and clinical information has been recently developed and validated to improve 
prostate cancer mortality (PCM) risk stratification over clinical features alone. As clinical 
features are currently used to select men for active surveillance (AS), we developed and 
validated a CCR score threshold to improve the identification of men with low-risk disease who 
are appropriate for AS.  
Methods: The score threshold was selected based on the 90th percentile of CCR scores among 
men who might typically be considered for AS based on NCCN low/favorable-intermediate risk 
criteria (CCR=0.8).  The threshold was validated using 10-year PCM in an unselected, 
conservatively managed cohort and in the subset of the same cohort after excluding men with 
high-risk features. The clinical impact was evaluated in a contemporary clinical cohort. 
Results: In the unselected validation cohort, men with CCR scores below the threshold had a 
predicted mean 10-year PCM of 2.7%, and the threshold significantly dichotomized low- and 
high-risk disease (p=1.2 x10-5).  After excluding high-risk men from the validation cohort, men 
with CCR scores below the threshold had a predicted mean 10-year PCM of 2.3%, and the 
threshold significantly dichotomized low- and high-risk disease (p=0.020). There were no 
prostate cancer-specific deaths in men with CCR scores below the threshold in either analysis. 
The proportion of men in the clinical testing cohort identified as candidates for AS was 
substantially higher using the threshold (68.8%) than using clinicopathologic features alone 
(42.6%), while mean 10-year predicted PCM risks remained essentially identical (1.9% vs. 
2.0%, respectively). 
Conclusions: CCR score thresholds appropriately dichotomize patients into low- and high-risk 
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1 INTRODUCTION 
Wide adoption of PSA screening has resulted in earlier prostate cancer diagnosis and is 
a likely factor in the reduction of disease-specific mortality [1,2]. However, this intensive 
population screening has also increased the identification of patients with indolent disease [3-5]. 
As a result, many men with screen-detected cancer are over-treated and needlessly suffer 
treatment-related side effects without a meaningful change in prognosis. Recent studies have 
shown that deferred treatment options, such as active surveillance (AS), are a safe way for men 
with newly diagnosed low-risk disease to minimize these adverse effects [6].  
Traditionally, patients have been selected for AS based on prognostic clinicopathologic 
variables that are evaluable at disease diagnosis, including Gleason score, PSA, clinical stage, 
PSA density, and percent of needle cores that contain tumor. However, better stratification of 
patients with low-grade localized disease is needed. In addition, AS selection criteria from the 
American Urological Association (AUA) [7] and National Comprehensive Cancer Network 
(NCCN) [8] differ and there are numerous additional variations in the literature [9-11]. 
Collectively, these uncertainties can lead to misclassification of patient risk and increased 
anxiety in both patients and physicians when selecting AS.  
A combined clinical cell-cycle risk (CCR) score has been recently developed to improve 
prostate cancer risk stratification. This score incorporates a prognostic molecular risk score 
based on the expression of 31 cell-cycle progression (CCP) genes [12,13] with clinicopathologic 
risk from the Cancer of the Prostate Risk Assessment (CAPRA) model [14]. This combined 
molecular and clinical model has been previously validated in a cohort of conservatively 
managed men and provides a superior discrimination of 10-year prostate cancer-specific 
mortality (PCM) risk relative to molecular or clinicopathologic parameters alone [15]. 
As clinicopathologic information is currently the standard for identifying men for AS, we 
hypothesized that the CCR score would improve the selection of men with low-risk prostate 
cancer who are appropriate for AS. To this end, we developed and validated a predefined CCR 
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score threshold to identify high- and low-risk disease in order to select suitable candidates for 
AS. The CCR score threshold was developed in men who might typically be considered for AS 
based on NCCN guidelines and validated in a cohort of conservatively managed men with long-
term clinical outcomes. In addition, we evaluated the ability of the CCR threshold scores to alter 
the selection of patients for AS in a contemporary clinical cohort of men with localized disease.  
 
2 MATERIALS AND METHODS 
2.1 Patients 
2.1.1 Training Cohort 
CCR score threshold was developed in a training cohort of men who underwent clinical 
testing (Myriad Genetic Laboratories, Salt Lake City, UT) between August 2012 and September 
2013 (N=1718). Samples were required to be from a post-2005 diagnostic biopsy and of good 
quality, as defined by having a mean Ct for housekeeper genes <22 (95th percentile of 
housekeeper Ct). All patients provided consent for clinical testing and all clinical information was 
obtained from the test request form (TRF).  
Clinicopathologic data from the TRF was used to select a subset of men who might be 
considered for AS based on modified NCCN guidelines (Figure 1). Specifically, we selected a 
subset of men with low/favorable intermediate-risk disease based on a conservative 
interpretation of NCCN guidelines: Gleason score ≤3+4; PSA <10 ng/mL; <25% positive cores; 
T-stage ≤T2a (N=505) [8]. This subset was used to select a CCR score threshold in men with 
low/favorable-intermediate clinicopathologic AS based NCCN guidelines. 
2.1.2 Validation Cohort 
The ability of the CCR score threshold to separate patients with high- and low-risk 
disease was validated in a cohort of conservatively managed men with needle biopsy-detected 
disease and long-term outcomes. Cases of adenocarcinoma of the prostate (N=585) diagnosed 
between 1990 and 2003 (median diagnosis date May 2002; IQR January 2001, May 2003) were 
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identified from three cancer registries in Great Britain (Figure 1). This cohort has been 
previously described and was used to validate the CCR score model, but not the CCR score 
threshold [15]. The full cohort description is provided in the Supplemental Materials. We also 
validated the threshold in a modified validation cohort that more closely resembles the spectrum 
of clinicopathologic features among men who may be considering AS.  This was done by 
evaluating the performance of the threshold after excluding men from the validation cohort with 
high-risk disease (PSA > 20 ng/ml or Gleason score ≥ 8 or clinical stage ≥ T2C).  Unless 
otherwise specified, risk estimates for DSM presented in this paper are based on risk curves 
derived from the entire validation cohort.  National ethics approval was obtained from the 
Northern Multicentre Research Ethics Committee, followed by local ethics committee approval 
at each collaborating hospital. 
2.1.3 Evaluation of AS Threshold in a Modern Clinical Cohort 
The potential clinical impact of selecting men for AS using the CCR threshold score was 
evaluated in a sequential, unselected set of 19,215 patients whose diagnostic biopsies were 
submitted for clinical testing (Myriad Genetic Laboratories) by their physician between October 
2013 and December 2016 (Figure 1). Patients underwent consent for testing and clinical data 
obtained from the TRF was used to determine whether patients met NCCN criteria for AS based 
on clinicopathologic features alone. Clinical follow-up was not collected as part of clinical 
testing.  
 
2.2 Molecular Testing 
All samples were processed as previously described [16]. In brief, the expression of 31 
CCP genes and 15 housekeeper genes was measured by quantitative RT-PCR. The CCP score 
was calculated as the un-weighted average of the CCP gene expression normalized by the 
average expression of the housekeeper genes [12,13]. The CCR score is the proportional 
hazard model combination of CAPRA (clinical variables) [14] and the molecular CCP score, 
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calculated as CCR=(0.39xCAPRA)+(0.57xCCP). This formula was optimized to predict adverse 
disease outcome in a study combining four previously published prostate cancer cohorts [17], 
and validated to predict 10-year PCM [15].  
 
2.3 Statistics  
The Firth penalized likelihood test was used to compare survival curves of patients in the 
validation cohort with CCR scores above and below the threshold score. Cox proportional 
hazards models were used to estimate the 10-year risk of PCM associated with the threshold 
score. The beta product confidence procedure for the Kaplan-Meier estimator was used to 
calculate a one-sided confidence interval (CI) for the negative predictive value (NPV) for 
patients with CCR scores below the threshold. Statistical analyses were conducted in R [18]. 
 
3 RESULTS 
3.1 Development of CCR Threshold Scores  
Table 1 describes the clinicopathologic features of men within the training cohort. There 
was a significant high-risk tail in the CCR score distributions within the subset of men with 
low/favorable-intermediate clinicopathologic features who might be considered for AS based on 
conservatively modified NCCN guidelines (Gleason score ≤3+4; PSA <10 ng/ml; <25% cores 
positive; clinical stage ≤T2a; Figure 2). This suggests that a proportion of men who present with 
low/favorable intermediate-risk clinical features may harbor higher risk disease and may not be 
good candidates for AS.  
To accommodate this, the 90th percentile of the CCR score distribution was 
conservatively selected as a proposed threshold to select men who are appropriate for AS. 
Using this cut-off, the CCR threshold score was 0.8 (rounded from 0.8334). Men with CCR 
scores equal to or below the threshold are considered candidates for AS. 
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3.2 Validation of CCR Score Threshold 
First, the CCR score threshold was validated in a cohort of 585 men who were 
conservatively managed, with the primary endpoint being PCM within the first 10 years of follow-
up (Table 1). There were 60 men (10%) with CCR scores below the threshold. The threshold 
score was highly predictive of high (CCR >0.8) and low risk (CCR ≤0.8) of 10-year PCM 
(p=0.00080, Figure 3A) and there were no observed deaths in men with CCR scores at or 
below the threshold. The estimated 10-year PCM risk was 2.7% for men with CCR scores below 
the threshold and the risk at the threshold was 3.3% (95% CI 1.94, 5.70). The NPV for the CCR 
score threshold was 100% (95% lower CI 89.5%). 525 men had CCR scores above the 
threshold and 87 prostate cancer deaths occurred in this group.  
Second, the threshold score was evaluated in modified validation cohort that excluded 
all men with high-risk clinicopathologic features (Table 1). The intent was to evaluate the 
performance of the AS threshold in a cohort that more closely matches the spectrum of risks in 
men who may be considering AS. The threshold score remained significantly predictive of high 
(CCR >0.8) and low risk (CCR ≤0.8) of 10-year PCM (p=0.02, Figure 3A). The estimated 10-
year PCM risk was 2.3% for men with CCR scores below the threshold and the risk at the 
threshold was 2.9% (95% CI; 1.25, 6.74).  As before, there were no observed deaths in men 
with CCR scores at or below the threshold so the calculation of NPV does not change, 
remaining at 100% NPV.   
As the clinical criteria for selecting AS candidates is highly variable [9,10], we also 
developed and validated AS thresholds based on either AUA [7] or CARPA [14] risk stratification 
(Supporting Information). The performance of these alternative thresholds was qualitatively 
similar to the threshold at 0.8 (Supplemental Table 1).    
Finally, we evaluated the performance of all thresholds to dichotomize high and low risk 
of biochemical recurrence after 10 years in a contemporary cohort of men with screen-detected 
prostate cancer treated by radical prostatectomy (Supporting Information, Supplemental 
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Table 4). This suggests that the threshold scores can differentiate high- and low-risk disease 
among treated men.  
 
3.3 Clinical Impact of the CCR Threshold Score in a Modern Clinical Cohort 
The potential clinical impact of identifying men for AS using the CCR score thresholds 
was evaluated in a consecutive group of 19,215 men who had clinical testing (Table 1). Overall, 
8,177 (42.6%) men in the clinical cohort met criteria for AS based on low/favorable intermediate-
risk clinicopathologic features. However, 13,221 of 19,215 (68.8%) men had CCR scores below 
the threshold (Table 2), with a mean 10-year PCM risk of 1.9%. Table 3 details of the 
cliniocopathologic features of the extended AS population defined by the threshold. Alternative 
thresholds based on either AUA or CAPRA risk stratification also dramatically increased the 
number of men who might be considered for AS compare to clinical features only 
(Supplemental Table 2).   
 
4 DISCUSSION 
Men with newly diagnosed prostate cancer are recommended for AS based on a low risk 
of having aggressive disease as defined by available clinical and pathologic information. An 
integrated assessment of risk that incorporates prognostic molecular (CCP score) and clinical 
variables (CAPRA) has been recently developed. This CCR score has been shown to improve 
risk stratification over clinical variables alone [15]. As men are traditionally selected for AS 
based only on clinicopathologic features, we developed CCR score thresholds to improve the 
identification of men with low-risk disease. 
The CCR score threshold was developed in men who might typically be considered 
appropriate for AS based on having low or favorable intermediate-risk disease according to a 
conservative interpretation of NCCN guidelines [8]. When the clinical performance was validated 
in conservatively managed men, the CCR score threshold significantly dichotomized men with 
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high- and low-risk of 10-year PCM (p=1.2x10-5 for the full validation cohort, or p=0.02 for the 
modified validation cohort). Depending on the patient composition of the validation cohort, men 
with CCR scores below the threshold had a predicted 10-year PCM risk of about 2.5%, while the 
NPV (probability of survival in patients with CCR scores equal to or below the threshold) was 
100% (95% lower CI 89.5%).  These analyses indicate that the threshold can be safely used to 
identify candidates for AS.   
The clinical impact of selecting men for AS using the CCR score threshold as evaluated 
in a modern commercial cohort and is two-fold. First, the estimated PCM risk should decrease 
among men considered candidates for AS based on their CCR score relative to those selected 
by clinicopathologic criteria. The threshold was developed based on the 90th percentile of men 
who fulfill the typical clinical criteria for AS. Patients in the top tenth percentile of CCR risk were 
excluded to minimize the potential of missing occult lethal disease. As such, men who had CCR 
scores below the threshold had an estimated 10-year PCM risk of less than 2%. In addition, the 
maximum estimated 10-year PCM risk was ~16% in men who qualify for AS based on 
low/favorable intermediate-risk clinicopatholgic criteria; however, this was reduced to ~3% when 
the CCR score threshold was applied. Second, application of the CCR score threshold should 
result in a substantial increase in the number of men identified as candidates for AS. Many men 
have low/favorable intermediate-risk disease, despite having some clinical features that would 
traditionally exclude them from AS. In this cohort, 42.6% of men were eligible for AS based on 
NCCN clinicopathologic criteria. However, 68.8% qualified for AS when the CCR score 
threshold was used to identify AS candidates. These data suggest that there is significant 
clinical utility in utilizing the CCR score thresholds to select men for AS.  
There are some limitations of this study, mostly related to the validation cohort. The 
validation cohort was composed of men who deferred curative therapy, but it was not a ‘true’ AS 
cohort in that there was little to no scheduled surveillance in the absence of symptoms of clinical 
progression.  The cohort was retrospectively collected in order to include patients with long-term 
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outcomes, which may introduce unknown biases in patient composition. However, it included 
patients from three independent cancer registries and employed disease population-based 
sample collection, both of which should reduce the potential for this bias. The validation cohort 
also contained relatively few low-risk men, which limits the precision of our estimate for NPV.  
And finally, the cohort contains higher risk men then typically consider AS which is a reflection 
of contemporaneous disease management in the UK.  As a result, the estimated risks for DSM 




Here we have shown that a CCR score threshold can be used to identify men with some higher-
risk features that nevertheless have low-risk disease as well as men with low-risk features and 
occult aggressive disease who are not appropriate for AS. Because retrospective studies have 
demonstrated that CCR score improves risk stratification compared to standard 
clinicopathologic features, clinical adoption of the threshold should enable improved 
identification of men with newly diagnosed localized prostate cancer who are appropriate for AS. 
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Figure 2. CCR score distribution in the training cohort (gray), with the NCCN-based subset 
(Gleason score ≤3+4; PSA <10 ng/ml; <25% positive cores; T-stage ≤T2a) in dark blue. The 
threshold score represents the 90th percentile for the low/favorable intermediate risk subset. 
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Figure 3. Kaplan-Meier plots showing prostate cancer mortality for patients in the validation 
cohort separated by CCR score threshold. The solid lines are for the full validation cohort 
(N=585) and dashed lines are for the modified validation cohort excluding men with high risk 
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Age at Diagnosis 
(yr) 
mean (sd) 68.3 (8.2) 69.5 (5.2) 68.7 (5.6) 64.5 (7.9) 
IQR 64.0 to 74.0 66.5 to 73.6 65.4 to 73.4 59.0 to 70.0 
PSA (ng/mL) 0 – 4 294 (17.1%) 15 (2.6%) 14 (4.9%) 3442 (17.9%) 
4.01 – 10 1120 (65.2%) 175 (29.9%) 149 (52.5%) 13,568 (70.6%) 
10.01 - 20 223 (13.0%) 163 (27.9%) 121 (42.6%) 1737 (9.0%) 
20.01 - 100 81 (4.7%) 232 (39.7%) 0 (0%) 468 (2.4%) 
median 5.9 16.0 9.2 5.6 
IQR 4.5 to 8.5 8.4 to 33.0 6.9 to 14.0 4.4 to 7.6 
Positive Cores 
(%) 
n 1718 585 284 19,215 
median 25.0 57.1 33.3 23.1 
IQR 16.0 to 42.0 33.3 to 87.5 22.9 to 60.6  12.5 to 35.7 
Gleason Score ≤4 1 (0.1%) 0 (0%) 0 (0%) 3 (<0.1%) 
5 3 (0.2%) 0 (0%) 0 (0%) 18 (0.1%) 
6 789 (45.9%) 151 (25.8%) 126 (44.4%) 12,004 (62.5%) 
3+4=7 597 (34.7%) 200 (34.2%) 158 (55.6%) 4716 (24.5%) 
4+3=7 191* (11.1%) 126 (21.5%) 0 (0%) 1555 (8.1%) 
8 86 (5.0%) 35 (6.0%) 0 (0%) 608 (3.2%) 
9 47 (2.7%) 66 (11.3%) 0 (0%) 286 (1.5%) 
10 4 (0.2%) 7 (1.2%) 0 (0%) 25 (0.1%) 
Clinical 
Stage 
T1a 33 (1.9%) 
87 (14.9%) 65 (22.9%) 
596 (3.1%) 
T1b 17 (1.0%) 174 (0.9%) 
T1c 1146 (66.7%) 14,993 (78.0%) 
T2a 221 (12.9%) 
371 (63.4%) 219 (77.1%) 
2225 (11.6%) 
T2b 179 (10.4%) 629 (3.3%) 
T2c 110 (6.4%) 529 (2.8%) 
T3a 9 (0.5%) 
127† (21.7%) 0 (0%) 
58 (0.3%) 
T3b 3 (0.2%) 11‡ (0.1%) 
AUA Risk 
Classification 
Low  648 (37.7%) 86 (14.7%) 86 (30.3%) 10,917 (56.8%) 
Intermediate  789 (45.9%) 198 (33.8%) 198 (69.7%) 6618 (34.4%) 
High  281 (16.4%) 301 (51.5%) 0 (0%) 1680 (8.7%) 
NCCN Risk** 
Classification 
Low 904 (52.6%) 22 (3.8%) 22 (7.7%) 10896 (56.7%) 
Favorable Intermediate 398 (23.2%) 
262 (44.8%) 262 (92.3%) 
3789 (19.7%) 
Intermediate 313 (18.2%) 3255 (16.9%) 
High 103 (6.0%) 301 (51.5%) 0 (0%) 1275 (6.6%) 
CAPRA Score Low (0 – 2) 848 (49.4%) 80 (13.7%) 80 (28.2%) 12,416 (64.6%) 
Intermediate (3 – 5) 687 (40.0%) 207 (35.4%) 174 (61.3%) 5543 (28.8%) 
High (≥6) 183 (10.7%) 298 (50.9%) 30 (10.6%) 1256 (6.5%) 
Includes one 5+2=7 
†Includes two T4 
‡Includes one T4 
** T stage subclassification was missing for some patients in validation cohort  
 
  19 
 
Table 2. Eligibility for AS according to clinicopathologic criteria and CCR score threshold in the 
clinical testing cohort (N=19,215). 
 
 
CCR Score ≤ 
Threshold 
CCR Score > 
Threshold 
Meet NCCN Criteria for AS (N=8177, 42.6%) 7463 (91.3%) 714 (8.7%) 
Do Not Meet NCCN Criteria for AS (N=11,038, 57.4%) 5758 (52.2%) 5280 (47.8%) 
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Table 3. Clinicopathologic features of patients in the clinical testing cohort who qualify for AS 





All Patients with 
CCR Score ≤ 0.8 
Meet NCCN 
Criteria for AS 
Do Not Meet NCCN 
Criteria for AS 
Total N (%) 13,221 (100%) 7463 (56.4%) 5758 (43.6%) 
Age at 
Diagnosis (yr) 
mean (sd) 64.0 (7.7) 64.2 (7.6) 63.7 (7.9) 
IQR 59.0 to 69.0 59.0 to 69.0 58.0 to 69.0 
PSA (ng/mL) 0 – 4 2912 (22.0%) 1790 (24.0%) 1122 (19.5%) 
4.01 – 10 9895 (74.8%) 5673 (76.0%) 4222 (73.3%) 
> 10 414 (3.1%) NA 414 (7.2%) 
Positive Cores 
(%) 
mean (sd) 22.4 (15.8) 12.5 (4.6) 35.1 (16.0) 
IQR 8.3 to 29.2 8.3 to 16.7 25.0 to 41.7 
Gleason Score ≤4 3 (<0.1%) 3 (4.0%) 0 (0%) 
5 14 (0.1%) 12 (16.1%) 2 (<0.1%) 
6 10,788 (81.6%) 6404 (85.8%) 4384 (76.1%) 
3+4=7 2359 (17.8%) 1044 (14.0%) 1315 (22.8%) 
4+3=7 38 (0.3%) NA 38 (0.7%) 
8 16 (0.1%) NA 16 (0.3%) 
9 3 (<0.1%) NA 3 (0.1%) 
10 0 (0%) NA 0 (0%) 
Clinical Stage T1a 474 (3.6%) 352 (4.7%) 122 (2.1%) 
T1b 129 (1.0%) 78 (1.0%) 51 (0.9%) 
T1c 10,765 (81.4%) 6233 (83.5%) 4532 (78.7%) 
T2a 1384 (10.5%) 800 (10.7%) 584 (10.1%) 
T2b 261 (2.0%) NA 261 (4.5%) 
T2c 199 (1.5%) NA 199 (3.5%) 
T3a 9 (0.1%) NA 9 (0.2%) 
T3b 0 (0%) NA 0 (0%) 
AUA Risk 
Classification 
Low  10,141 (76.7%) 6419 (86.0%) 3722 (64.6%) 
Intermediate  2844 (21.5%) 1044 (14.0%) 1800 (31.3%) 
High  236 (1.8%) NA 236 (4.1%) 
CAPRA Score Low (0 – 2) 11,552 (87.4%) 7228 (96.9%) 4324 (75.1%) 
Intermediate (3 – 5) 1669 (12.6%) 235 (3.1%) 1434 (24.9%) 








Identification of Men with Low-Risk Biopsy-Confirmed Prostate Cancer as Candidates for 
Active Surveillance 
 
Evaluating Additional Thresholds 
 There are numerous criteria used in the clinic to select patients for AS. [1-5] As such, we have 
developed and evaluated two additional AS thresholds based on AUA and CAPRA risk stratification.   
 
Cohorts 
CCR score thresholds based on AUA and CAPRA risk stratification were developed in the same 
training cohort described in the main text (N=1718). A subset of men with low-risk disease who may be 
considered for AS was selected based on a conservative interpretation of AUA guidelines: Gleason score 
≤3+3; PSA <10 ng/mL; <25% positive cores; T-stage ≤T2a (N=385) [2,5,6]. This subset of the training 
cohort was used to select a CCR score threshold in men with low-risk clinicopathologic who would be 
considered for AS according to AUA guidelines (AUA score threshold). Second, a subset of men was 
selected from the training cohort based on having low-risk CARPA scores (0-2) [7]. This subset of the 
training cohort was used to select a CCR score threshold in men with low-risk clinicopathologic who 
would be considered for AS according to CAPRA (CAPRA threshold).   
The ability of the CCR score thresholds to separate patients with high- and low-risk disease was 
validated in the same cohort of conservatively managed men with long-term outcomes described in the 
main text [8]. Both the full validation cohort (N=585) and modified validation cohort that excluded men 




 CCR-based risk distributions were calculated for men who may qualify for AS based on AUA 
guidelines (Gleason score ≤3+3; PSA <10 ng/ml; <25% cores positive; clinical stage ≤T2a) and for men 
who may qualify for AS based on CAPRA scores 0-2. The 90th percentile of the CCR score distribution in 
each subset was conservatively selected as a proposed threshold to select men who are appropriate for 
AS.  Using this cut-off, the CCR threshold score was 0.6 (rounded from 0.552) in men would be 
considered for AS based on AUA criteria (AUA score threshold) and 0.7 (rounded from 0.723) in men 
who would be considered for AS based on CAPRA scores 0-2.  The performance of these thresholds in 
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the entire validation cohort and in the modified validation cohort is summarized in Supplemental Table 
1.   
 The potential clinical impact of identifying men for AS using these alternative CCR score 
thresholds was evaluated in a consecutive group of 19,215 men who had clinical testing (Clinical Testing 
Cohort).  A comparison of men above and below the thresholds to men who would and would have not 
qualified for AS based on clinicopathologic criteria alone is shown in Supplemental Table 2. 
 
 
Evaluation of CCR Score Thresholds in RP Treated Cohort 
In addition to selecting men for active surveillance, stratifying risk is also of value in men with 
localized prostate cancer who have been treated and may improve identification of men who will 
benefit from treatment. To explore the utility of the CCR score thresholds to dichotomize high- and low-
risk disease, we evaluated the score thresholds in men with screen-detected disease who were treated 
for localized prostate cancer by radical prostatectomy (RP). This cohort has been previously described 
and includes men who were diagnosed at three different clinics/hospitals between 1994 and 2006 
(N=581).[9] Of these, 416 had complete data for calculating CAPRA score.  IRB approval was obtained for 
all study sites. Follow-up included biochemical recurrence (BCR) data, which were censored at 10 years.  
The clinicopathologic features of this cohort are given in Supplemental Table 3. All three 
thresholds (AUA, CAPRA, and NCCN) were highly predictive (log-rank test), dichotomizing the cohort into 
high and low risk of BCR. The hazard ratio (HR) for men with CCR scores below the AUA threshold was 
0.45 (95% CI: 0.28, 0.73, p= 8.8 x10-4). The hazard ratio (HR) for men with CCR scores below the CAPRA 
threshold was 0.47 (95% CI: 0.30, 0.74, p=9.2x10-4).  And finally, hazard ratio (HR) for men with CCR 
scores below the NCCN threshold was 0.45 (95%CI: 0.30, 0.69, p=1.7x10-4). The number of observed 
events among men with CCR scores above and below the thresholds is given in Supplemental Table 4. 
For example, only 12% of men with CCR scores below the NCCN threshold had BCR within 5 years of RP 
compared to 31% of men with scores above the NCCN threshold. This provides preliminary evidence 
that the CCR score thresholds are also able to dichotomize disease risk in treated men 
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Supplemental Table 1. Validation of the AUA- and CAPRA-based CCR threshold scores. The validation of 
the original CCR threshold developed based on NCCN criteria is provided for comparison.  
 CCR Score = Threshold CCR Score < Threshold   
CCR Threshold Score 
Mean Risk of 10-year 
DSM (95% CI) 
Mean Risk of 
10-year DSM 
Events Patients NPV p-value* 
Full Validation Cohort (N=585) 
AUA (Threshold = 0.6) 2.8% (1.60, 5.03)  2.30% 0 32 100% 0.0027 
CAPRA (Threshold = 0.7) 3.1% (1.80, 5.44) 2.50% 0 46 100% 1.6x10-4 
NCCN (Threshold = 0.8) 3.3% (1.94, 5.70) 2.70% 0 60 100% 1.2x10-5 
Modified Validation Cohort (Excluding men with high risk clinicopathologic features; N=284) 
AUA (Threshold = 0.6) 2.4% (0.95,6.19)  1.90% 0 28 100% 0.16 
CAPRA (Threshold = 0.7) 2.7% (1.09, 6.45) 2.10% 0 45 100% 0.052 
NCCN (Threshold = 0.8) 2.9% (1.25, 6.74) 2.30% 0 59 100% 0.020 






Supplemental Table 2. Eligibility for AS according to clinicopathologic criteria and CCR score threshold in 
the clinical testing cohort (N=19,215). 
 
CCR Score ≤ 
Threshold 
CCR Score > 
Threshold 
AUA Threshold (CCR score 0.6) 
Meet AUA Criteria for AS  89.5% 10.5% 
Do Not Meet AUA Criteria for AS  44.7% 55.3% 
Total 60.3% 39.7% 
CAPRA Threshold (CCR score 0.7) 
Meet CAPRA score 0-2 for AS  89.4% 10.6% 
Do Not Meet CAPRA score 0-2 for AS  18.4% 81.6% 
Total 64.3% 35.7% 
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Age at Diagnosis 
(yr) 
mean (sd) 62.0 (6.5) 
IQR (57.9 to 66.6) 
PSA (ng/mL) 0 – 4 84 (14.5%) 
4.01 – 10 363 (62.5%) 
10.01 - 20 109 (18.8%) 
20.01 - 100 25 (4.3%) 
median 6.4 





IQR (20.0 to 50.0) 
Gleason Score ≤4 6 (1.0%) 
5 44(7.6%) 
6 288 (49.6%) 
3+4=7 124 (21.3%) 
4+3=7 41 (7.1%) 
7 38 (6.5%) 
8 29 (5.0%) 
9 8 (1.4%) 
10 3 (0.5%) 
Clinical 
Stage 
T1a 0 (0%) 
T1b 0 (0%) 
T1c 356 (65.2%) 
T2a 153 (28.0%) 
T2b 24 (4.4%) 
T2c 9 (1.6%) 
T3a 4 (0.7%) 
T3b 0 (0%) 
AUA Risk 
Classification 
Low  63 (16.8%) 
Intermediate  241 (64.3%) 
High  71 (18.9%) 
CAPRA Score Low (0 – 2) 202 (48.6%) 
Intermediate (3 – 5) 187 (45.0%) 
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Supplemental Table 4. BCR within 5 years of RP according to AS eligibility (CCR ≤ threshold). 
 
CCR Score 
No BCR within 5 years of RP 
N 
BCR within 5 years of RP 
N (%) 
AUA Threshold (CCR score 0.6) 
CCR Score ≤ Threshold 119 14 (11%) 
CCR Score > Threshold 200 83 (29%) 
CAPRA Threshold (CCR score 0.7) 
CCR Score ≤ Threshold 130 15 (10%) 
CCR Score > Threshold 189  82 (30%) 
NCCN Threshold (CCR score 0.8) 
CCR Score ≤ Threshold 145 19 (12%) 
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